Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.

about

UNBS5162 inhibits the proliferation of human A549 non-small-cell lung cancer cells by promoting apoptosis.

P2860

Q47410522-59E02DF7-750E-4B89-8CAB-18DC0DF62385

P2860

Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.

Item

http://www.wikidata.org/entity/Q42070616

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Efficacy of the dual PI3K and ...... elogenous leukemia cell lines.

@en

Efficacy of the dual PI3K and ...... elogenous leukemia cell lines.

@nl

type

Item

label

Efficacy of the dual PI3K and ...... elogenous leukemia cell lines.

@en

Efficacy of the dual PI3K and ...... elogenous leukemia cell lines.

@nl

prefLabel

Efficacy of the dual PI3K and ...... elogenous leukemia cell lines.

@en

Efficacy of the dual PI3K and ...... elogenous leukemia cell lines.

@nl

P1476

Efficacy of the dual PI3K and ...... elogenous leukemia cell lines.

@en

P2093

Chuntuan Li

http://www.w3.org/2001/XMLSchema#string

Huifang Xiao

http://www.w3.org/2001/XMLSchema#string

Pengliang Xin

http://www.w3.org/2001/XMLSchema#string

Qunyi Peng

http://www.w3.org/2001/XMLSchema#string

Xiongpeng Zhu

http://www.w3.org/2001/XMLSchema#string

Yan Zheng

http://www.w3.org/2001/XMLSchema#string

Yuanling Huang

http://www.w3.org/2001/XMLSchema#string

P2860

NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer.

The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors

NVP-BEZ235 overcomes gefitinib-acquired resistance by down-regulating PI3K/AKT/mTOR phosphorylation.

Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer

Morphoproteomics: exposing protein circuitries in tumors to identify potential therapeutic targets in cancer patients.

PI3K/Akt/mTOR pathway as a target for cancer therapy.

P304

1115-1126

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/DDDT.S132092

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28435223

http://www.w3.org/2001/XMLSchema#string

P932

5388256

http://www.w3.org/2001/XMLSchema#string

Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.

about

P2860

P2860

Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P932